Chest
Assessment of Tachyphylaxis following Prolonged Therapy of Asthma with Inhaled Albuterol Aerosol
Section snippets
METHODS
One hundred forty patients were evaluated at eight different centers. The number of patients evaluated at each center varied from 11 to 32. Twenty-eight patients from one center were excluded from the final statistical analysis because the results obtained from this center were at such striking variance with the results obtained from the seven other centers. Even though it is statistically invalid to analyze the variant center's results along with the overall results, the inclusion of these
RESULTS
Figures 1, 2, and 3, derived from Tables 3 and 4, indicate that there is evidence of tachyphylaxis after inhaling two puffs of albuterol aerosol four times a day for 91 days. This is true, however, only with regard to the duration of significant bronchodilator response, but not with regard to peak bronchodilator effect, although there was an absolute drop of 0.139 L (16 percent) from 0.875 L at week zero to 0.736 L at week 13. Quantitatively the amount of tachyphylaxis with respect to the
DISCUSSION
It has been accepted practice in the United States to use long-duration beta2 specific adrenergic aerosols, specifically isoetherine and metaproterenol, as therapy for a variety of bronchospastic pulmonary disorders. However, previously published reports about tachyphylaxis with adrenergic agonists have raised reasonable concern about this therapy, particularly when the use of adrenergic aerosol inhalers has been abused. Fortunately, there have been no reports of “epidemics” of asthmatic deaths
ACKNOWLEDGMENT
The authors thank Miss Nicolette Cavallaro for her editorial assistance in the preparation of this manuscript.
REFERENCES (11)
- et al.
Selectivity of bronchodilator action of salbutamol in asthmatic patients
Br J Dis Chest
(1971) - et al.
Use of exercise challenge to investigate possible tolerance to beta2 adrenoceptor stimulation in asthma
Br J Dis Chest
(1978) - et al.
Effect of salbutamol on spirometry and blood-gas tensions in bronchial asthma
Br Med J
(1969) - et al.
Salbutamol and isoproterenol, a double-blind trial to compare bronchodilator and cardiovascular activity
N Engl J Med
(1969) Physiology and pharmacology of beta2 adrenergic agents
Chest
(1978)
Cited by (84)
Is there a problem with inhaled long-acting β-adrenergic agonists?
2006, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The clinical significance of this loss of bronchodilator response can be debated. However, if the duration of time that the FEV1 value remains 15% greater than baseline is used as a measure of continuing significant bronchodilation, this is decreased by approximately 50% as subsensitivity develops.16 On the other hand, the peak bronchodilator effect is better preserved, and thus the short-acting β2-adrenergic bronchodilators continue to perform well as rescue medication, even after development of subsensitivity.
Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma
2001, Annals of Allergy, Asthma and ImmunologyComparison of powder and aerosol formulations of salmeterol in the treatment of asthma
2000, Annals of Allergy, Asthma and ImmunologyRisks and benefits of asthma therapies
2000, Allergology InternationalThe pathobiologic implications for treatment: Old and new strategies in the treatment of chronic asthma
2000, Clinics in Chest MedicineCitation Excerpt :The mechanisms that lead to decreased responsiveness of the β2 receptors are desensitization (reduced receptor responsiveness to β agonists or other agonists) and downregulation of β2 receptors. Tolerance to the bronchodilator effects of both short- and long-acting β agonists has been demonstrated in some, but not all, clinical studies. 123,125,143 The effect, when present, however, is usually small and remains of questionable clinical significance.
Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled β-agonist treatment
2000, Respiratory Medicine
Supported by a grant from the Schering-Plough Research Division, Bloomfield, New Jersey.
Manuscript received April 12, 1982; revision accepted July 18.